Fundraising Fox

Consano Bio

Burlington, US · Founded 2022 · Delaware corporation

Biotech

Founders & leadership

AH
Andrew HallChief Executive Officer and Secretary of Issuer
JS
Jennifer SchmitkePresident and Chief Operating Officer of Issuer
DH
DANIEL HADERSNamed on SEC filing
WS
WAYNE SCHELLHAMMERNamed on SEC filing
CH
CLAYTON HARTMANNamed on SEC filing

Board

BA
Bill AbbingtonBoard director
JA
Jerome AdamsBoard director
DV
Doug Vander WeideBoard director
CC
Chris CentenoBoard director

Reported raises · per SEC filings

Form D private placements

$59.6M disclosed across 3 rounds · 2023–2026

▶$34.8MraisedMar 2026 · 28 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael PedeDirector
  • Bill AbbingtonDirector
  • John ConwayDirector
  • Joe SchieslDirector
  • Jennifer SchmitkeExecutive Officer
  • Christopher CentenoDirector
  • Doug Vander WeideDirector
  • Andrew HallExecutive Officer, Director
  • Jerome AdamsDirector
Offering amount
$48.9M
Amount sold
$34.8M
First sale
Mar 2026
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.8MraisedDec 2025 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bill AbbingtonDirector
  • Jerome AdamsDirector
  • Doug Vander WeideDirector
  • Chris CentenoDirector
  • Andrew HallExecutive Officer, Director
  • Jennifer SchmitkeExecutive Officer
Offering amount
$16.8M
Amount sold
$16.8M
First sale
Oct 2024
Incorporated
Corporation, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.9MraisedJun 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • DANIEL HADERSDirector
  • WAYNE SCHELLHAMMERExecutive Officer, Director
  • CLAYTON HARTMANDirector
  • NA REGENEXX HOLDINGS, LLCExecutive Officer
Offering amount
$12M
Amount sold
$7.9M
Minimum investment
$100K
First sale
Jun 2023
Incorporated
Limited Liability Company, Delaware, 2022
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

FDA Grants Fast Track Status to Consano Bio’s Chronic Sciatica Drug - Pharma Journalistpharmajournalist.com · Aug 2026FDA Grants Fast Track Designation to Consano Bio's Platelet-Derived Biologic C-1101 for Chronic Sciatica | BioPharm Internationalbiopharminternational.com · Aug 2026Consano Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United Statesprnewswire.com · Jul 2026Consano Bio to Present at BIO Investment & Growth Summit 2026finance.yahoo.com · Feb 2026Program - BIO Investment & Growth Summit 2026bigs.bio.org

Frequently asked questions

How much funding has Consano Bio raised?
Consano Bio has disclosed $59.6M raised across 3 rounds.
Where is Consano Bio headquartered?
Consano Bio is headquartered in Burlington, US.